Show item record

dc.contributor.authorFontaine, Jennifer
dc.contributor.authorChin, Evelyn
dc.contributor.authorProvencher, Jean-François
dc.contributor.authorRainone, Anthony
dc.contributor.authorWazzan, Dana
dc.contributor.authorRoy, Carmella
dc.contributor.authorRej, Soham
dc.contributor.authorLordkipanidzé, Marie
dc.contributor.authorDagenais-Beaulé, Vincent
dc.date.accessioned2022-05-02T13:11:35Z
dc.date.availableNO_RESTRICTIONfr
dc.date.available2022-05-02T13:11:35Z
dc.date.issued2022
dc.identifier.urihttp://hdl.handle.net/1866/26637
dc.publisherBMJ Publishing Groupfr
dc.rightsCe document est mis à disposition selon les termes de la Licence Creative Commons Attribution - Pas d’utilisation commerciale 4.0 International. / This work is licensed under a Creative Commons Attribution - NonCommercial 4.0 International License.
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.titleAssessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic : the CAMI-SGA study – a crosssectional studyfr
dc.typeArticlefr
dc.contributor.affiliationUniversité de Montréal. Faculté de pharmaciefr
dc.identifier.doi10.1136/bmjopen-2021-055454
dcterms.abstractObjectives This study aims to determine the proportion of initial cardiometabolic assessment and its predicting factors in adults with schizophrenia, bipolar disorder or other related diagnoses for whom a second-generation antipsychotic was prescribed in the hospital setting. Design Cross-sectional study. Setting The psychiatry unit of a Canadian tertiary care teaching hospital in Montreal, Canada. Participants 402 patients with aforementioned disorders who initiated, restarted or switched to one of the following antipsychotics: clozapine, olanzapine, risperidone, paliperidone or quetiapine, between 2013 and 2016. Primary outcome measures We assessed the proportion of cardiometabolic parameters monitored. Secondary outcome measures We identified predictors that influence the monitoring of cardiometabolic parameters and we assessed the proportion of adequate interventions following the screening of uncontrolled blood pressure and fasting glucose or glycated haemoglobin (HbA1c) results. Results Only 37.3% of patients received monitoring for at least three cardiometabolic parameters. Blood pressure was assessed in 99.8% of patients; lipid profile in 24.4%; fasting glucose or HbA1c in 33.3% and weight or body mass index in 97.8% of patients while waist circumference was assessed in 4.5% of patients. For patients with abnormal blood pressure and glycaemic values, 42.3% and 41.2% subsequent interventions were done, respectively. The study highlighted the psychiatric diagnosis (substance induced disorder OR 0.06 95% CI 0.00 to 0.44), the presence of a court-ordered treatment (OR 0.79 95% CI 0.35 to 1.79) and the treating psychiatrist (up to OR 34.0 95% CI 16.2 to 140.7) as predictors of cardiometabolic monitoring. Conclusions This study reports suboptimal baseline cardiometabolic monitoring of patients taking an antipsychotic in a Canadian hospital. Optimising collaboration within a multidisciplinary team may increase cardiometabolic monitoring.fr
dcterms.isPartOfurn:ISSN:2044-6055fr
dcterms.languageengfr
UdeM.ReferenceFournieParDeposantDOI--https://bmjopen.bmj.com/content/12/4/e055454fr
UdeM.VersionRioxxVersion publiée / Version of Recordfr
oaire.citationTitleBMJ Openfr
oaire.citationVolume12fr


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show item record

Ce document est mis à disposition selon les termes de la Licence Creative Commons Attribution - Pas d’utilisation commerciale 4.0 International. / This work is licensed under a Creative Commons Attribution - NonCommercial 4.0 International License.
Usage rights : Ce document est mis à disposition selon les termes de la Licence Creative Commons Attribution - Pas d’utilisation commerciale 4.0 International. / This work is licensed under a Creative Commons Attribution - NonCommercial 4.0 International License.